Comparative Efficacy and Safety of Pharmacological Managements for Hospitalized COVID-19 Patients: Protocol for Systematic Review and Trade-Off Network Meta-Analysis.
Kim, M. S.; Kim, W. J.; An, M. H.
Show abstract
Coronavirus-Disease 2019 (COVID-19) is the clinical disease caused by the SARS-CoV-2 virus, the infectious agent causing the ongoing pandemic that has impacted the lives of hundreds of millions of people in almost every nation worldwide. It is a potentially fatal disease to many vulnerable patients including the elderly and those with chronic illnesses; but because this virus is a novel one, there are no firmly established treatment protocols. Many treatment methods are being investigated worldwide, and scientific conclusions drawn from these endeavors are crucial for healthcare professionals in combating this disease. In this network meta-analysis, we focus specifically on the pharmacologic agents that have been investigated for the treatment of COVID-19 and aim to produce a comprehensive picture of the evidence from current data in order to produce relevant insights on the comparative efficacy and safety profiles of various pharmacologic agents against COVID-19.
Matching journals
The top 11 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Repurposing Existing Medications for Coronavirus Disease 2019: Protocol for a Rapid and Living Systematic Review 95%
- Evidence-Based, Cost-Effective Interventions To Suppress The COVID-19 Pandemic: A Systematic Review 92%
- Preventing respiratory illness in older adults aged 60 years and above living in long-term care: A rapid overview of reviews 90%
Similar papers in this journal
- Favipiravir for treating novel coronavirus (COVID-19) patients: protocol for a systematic review and meta-analysis of controlled trials 96%
- Efficacy of remdesivir versus placebo for the treatment of COVID-19: A protocol for systematic review and meta-analysis of randomized controlled trials 95%
- Adverse effects of remdesivir, hydroxychloroquine, and lopinavir/ritonavir when used for COVID-19: systematic review and meta-analysis of randomized trials 93%
Similar papers in this journal
- The Effect of Famotidine on Hospitalized Patients with COVID-19: a Systematic Review and Meta-analysis 93%
- On the treatment effect heterogeneity of antidepressants in major depression. A Bayesian meta-analysis 92%
- A Multicenter, randomized, open-label, controlled trial to evaluate the efficacy and tolerability of hydroxychloroquine and a retrospective study in adult patients with mild to moderate Coronavirus disease 2019 (COVID-19) 92%
Similar papers in this journal
- Coronavirus Disease (COVID-19) Pandemic: An Overview of Systematic Reviews 94%
- Janus Kinase-Inhibitor and Type I Interferon Ability to Produce Favorable Clinical Outcomes in COVID-19 Patients: A Systematic Review and Meta-Analysis 93%
- Comparison of renin-angiotensin-aldosterone system inhibitors with other antihypertensives in association with coronavirus disease-19 clinical outcomes: systematic review and meta-analysis 92%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.